


CLAIMS

1. A compound of the formula



5

in which the aminosulfonyl group is attached at the  
3- or 4-position, and in which

10        R<sup>1</sup> is hydrogen, C<sub>1</sub>-6 alkyl, C<sub>3</sub>-10 cycloalkyl, C<sub>3</sub>-10  
          cycloalkyl-C<sub>1</sub>-4 alkyl or optionally substituted  
          phenyl-C<sub>1</sub>-4 alkyl.

15        R<sup>2</sup> is C<sub>1</sub>-6 alkyl, C<sub>3</sub>-10 cycloalkyl, C<sub>3</sub>-10  
          cycloalkyl-C<sub>1</sub>-4 alkyl, optionally substituted

phenyl-C<sub>1-4</sub> alkyl or -(CH<sub>2</sub>)<sub>2</sub>NR<sup>5</sup>R<sup>6</sup> where R<sup>5</sup> and R<sup>6</sup> are each hydrogen or C<sub>1-6</sub> alkyl, and

R<sup>3</sup> and R<sup>4</sup> are each C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl,  
5 C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, C<sub>3-6</sub> alkenyl,  
optionally substituted phenyl or optionally  
substituted phenyl-C<sub>1-4</sub> alkyl,

10 or R<sup>1</sup> and R<sup>2</sup>, or R<sup>3</sup> and R<sup>4</sup>, or R<sup>5</sup> and R<sup>6</sup>, together  
with the nitrogen atom to which they are attached,  
form a carbocyclic group containing 4 to 7 carbon  
atoms optionally substituted with one to three  
methyl or ethyl groups and optionally containing an  
oxygen atom or a further nitrogen atom, said  
15 carbocyclic group being optionally fused to an  
optionally substituted phenyl group;

or a salt thereof.

20 2. A compound according to Claim 1 in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>  
and R<sup>4</sup> are each C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub>  
cycloalkyl-C<sub>1-4</sub> alkyl or optionally substituted  
phenyl-C<sub>1-4</sub> alkyl, and R<sup>1</sup> can in addition be  
hydrogen, or R<sup>1</sup> and R<sup>2</sup>, or R<sup>3</sup> and R<sup>4</sup> together with

4 9 0 3 1 4 2 2 . 0 3 0 9 0 2

the nitrogen atom to which they are attached, form a carbocyclic group.

3. A compound according to Claim 2 in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl or optionally substituted phenyl-C<sub>1-4</sub> alkyl, and R<sup>1</sup> can in addition be hydrogen.
- 10 4. A compound according to Claim 3 in which R<sup>1</sup> is hydrogen, R<sup>2</sup> is optionally substituted phenyl-C<sub>1-4</sub> alkyl and R<sup>3</sup> and R<sup>4</sup> are C<sub>1-6</sub> alkyl.
- 15 5. A compound according to Claim 1 in which R<sup>2</sup> is -(CH<sub>2</sub>)<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>.
- 20 6. A compound according to Claim 1 or 5 in which R<sup>3</sup> or R<sup>4</sup> is C<sub>3-6</sub> alkyl or when R<sup>3</sup> and R<sup>4</sup> are taken together with the nitrogen atom they form a piperidine ring which is substituted at the 3- and/or 5-positions with one or two methyl or ethyl substituents.

10031122 040902

- 34 -

7. A pharmaceutical formulation comprising a compound according to any of Claims 1 to 6 or a pharmaceutically acceptable salt thereof, together with a diluent or carrier therefor.

5

8. A compound according to any of Claims 1 to 6, for use as a pharmaceutical.

9. Use of a compound according to any of Claims 1 to

10 6, in the manufacture of a medicament for treating a disorder of the central nervous system.

10. A method of treating a disorder of the central nervous system which comprises administering an effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

100031122 " 010602